{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:26Z","timestamp":1786983866480,"version":"build-2736575974"},"reference-count":156,"publisher":"Elsevier","isbn-type":[{"value":"9780443141645","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015358","name":"American Society of Clinical Psychopharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015358","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019120","name":"Otsuka America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019120","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.02.002","type":"book-chapter","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T09:06:44Z","timestamp":1710234404000},"page":"153-185","source":"Crossref","is-referenced-by-count":6,"title":["Repurposing drugs for treatment of alcohol use disorder"],"prefix":"10.1016","member":"78","reference":[{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib1","first-page":"67","article-title":"Ability of baclofen in reducing alcohol craving and intake: II\u2014Preliminary clinical evidence","volume":"24","author":"Addolorato","year":"2000","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/alcalc\/37.5.504","article-title":"Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study","volume":"37","author":"Addolorato","year":"2002","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"issue":"12","key":"10.1016\/bs.irn.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S2215-0366(18)30303-1","article-title":"Baclofen for the treatment of alcohol use disorder: The Cagliari Statement","volume":"5","author":"Agabio","year":"2018","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib4","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: A self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib5","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21f13980","article-title":"Prazosin for alcohol use disorder: A symptom-driven approach to the choice of intervention","volume":"82","author":"Andrade","year":"2021","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib6","article-title":"Co-occurring alcohol use disorder and anxiety: Bridging psychiatric, psychological, and neurobiological perspectives","volume":"40","author":"Anker","year":"2019","journal-title":"Alcohol Research"},{"issue":"17","key":"10.1016\/bs.irn.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA: The Journal of the American Medical Association"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: A randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib9","article-title":"Alcohol use disorder and schizophrenia or schizoaffective disorder","volume":"40","author":"Archibald","year":"2019","journal-title":"Alcohol Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib10","unstructured":"Ardeljan, A. D., & Hurezeanu, R. (2023). Lemborexant. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Razvan Hurezeanu declares no relevant financial relationships with ineligible companies: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e3181db38bb","article-title":"Placebo-controlled trial of zonisamide for the treatment of alcohol dependence","volume":"30","author":"Arias","year":"2010","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drugalcdep.2013.04.025","article-title":"Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption","volume":"133","author":"Aubin","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib13","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/alcalc\/agab029","article-title":"Use of nalmefene in routine practice: Results from a french prospective cohort study and a national database analysis","volume":"56","author":"Aubin","year":"2021","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.02.002_bib14","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1111\/acer.12907","article-title":"Feeding two birds with one scone: The case of varenicline","volume":"39","author":"Aubin","year":"2015","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bcp.12116","article-title":"Pharmacotherapy for smoking cessation: Pharmacological principles and clinical practice","volume":"77","author":"Aubin","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000371547","article-title":"Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients","volume":"21","author":"Aubin","year":"2015","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib17","unstructured":"Autry, B. M., & Wadhwa, R. (2023). Mifepristone. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Roopma Wadhwa declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"key":"10.1016\/bs.irn.2024.02.002_bib18","unstructured":"Basquez, R., & Pippin, M. M. (2023). Prazosin. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Micah Pippin declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2217\/pgs.15.72","article-title":"Serotonergic gene variation in substance use pharmacotherapy: A systematic review","volume":"16","author":"Bauer","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/bs.irn.2024.02.002_bib20","doi-asserted-by":"crossref","DOI":"10.1111\/acer.12411","article-title":"A meta-analysis of topiramate's effects for individuals with alcohol use disorders","author":"Blodgett","year":"2014","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/acps.12905","article-title":"Baclofen for alcohol use disorder-a systematic meta-analysis","volume":"138","author":"Bschor","year":"2018","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1186\/s13063-020-04670-y","article-title":"Ibudilast for alcohol use disorder: Study protocol for a phase II randomized clinical trial","volume":"21","author":"Burnette","year":"2020","journal-title":"Trials"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/bs.irn.2024.02.002_bib24","first-page":"4654","article-title":"Clinical applications of sodium oxybate (GHB): From narcolepsy to alcohol withdrawal syndrome","volume":"19","author":"Busard\u00f2","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2024.02.002_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.08.005","article-title":"A sleeping giant: Suvorexant for the treatment of alcohol use disorder?","volume":"1731","author":"Campbell","year":"2020","journal-title":"Brain Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146597","article-title":"Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial","volume":"1728","author":"Campbell","year":"2020","journal-title":"Brain Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/YCO.0000000000000512","article-title":"Selecting an appropriate alcohol pharmacotherapy: Review of recent findings","author":"Castren","year":"2019","journal-title":"Current Opinion in Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/13543784.2018.1472763","article-title":"Investigational drugs for alcohol use disorders: A review of preclinical data","volume":"27","author":"Ch\u2019Ng","year":"2018","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2515\/therapie\/2015027","article-title":"Use in France of baclofen for alcohol dependence from 2007 to 2013: Cohort study based on the databases SNIIRAM and PMSI","volume":"70","author":"Chaignot","year":"2015","journal-title":"Therapie"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib31","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0000000000000130","article-title":"The effects of quetiapine on sleep in recovering alcohol-dependent subjects: A pilot study","volume":"34","author":"Chakravorty","year":"2014","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"16","key":"10.1016\/bs.irn.2024.02.002_bib32","article-title":"A 10-year study of factors associated with alcohol treatment use and non-use in a U.S. population sample","volume":"16","author":"Chartier","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.02.002_bib33","first-page":"e2751","article-title":"Gabapentinoids for treatment of alcohol use disorder: A systematic review and meta-analysis","author":"Cheng","year":"2020","journal-title":"Human Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib34","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fpsyt.2018.00475","article-title":"Suppressing effect of baclofen on multiple alcohol-related behaviors in laboratory animals","volume":"9","author":"Colombo","year":"2018","journal-title":"Frontiers in Psychiatry"},{"issue":"708","key":"10.1016\/bs.irn.2024.02.002_bib35","first-page":"708","article-title":"The use of baclofen as a treatment for alcohol use disorder: A clinical practice perspective","volume":"9","author":"De Beaurepaire","year":"2018","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2024.02.002_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/acer.12854","article-title":"Varenicline for treatment of alcohol dependence: A randomized, placebo-controlled trial","author":"De Bejczy","year":"2015","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib37","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/acer.14674","article-title":"Alcohol use disorder severity moderates clinical response to varenicline","volume":"45","author":"Donato","year":"2021","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1186\/s13063-020-04726-z","article-title":"Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence","volume":"21","author":"Donoghue","year":"2020","journal-title":"Trials"},{"issue":"7","key":"10.1016\/bs.irn.2024.02.002_bib39","first-page":"660","article-title":"N-acetylcysteine in the treatment of craving in substance use disorders: Systematic review and meta-analysis","volume":"26","author":"Duailibi","year":"2017","journal-title":"The American Journal on Addictions\/American Academy of Psychiatrists in Alcoholism and Addictions"},{"key":"10.1016\/bs.irn.2024.02.002_bib40","unstructured":"Ershad, M., Naji, A., & Vearrier, D. (2023). N-Acetylcysteine. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Abdullah Naji declares no relevant financial relationships with ineligible companies. Disclosure: David Vearrier declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib41","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/bs.irn.2024.02.002_bib42","unstructured":"European-Medicines-Agency. (2010). Guideline on the development of medicinal products for the treatment of alcohol dependence. Retrieved from \u3008http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf\u3009."},{"issue":"4","key":"10.1016\/bs.irn.2024.02.002_bib43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0000000000000133","article-title":"Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: An exploratory analysis","volume":"9","author":"Falk","year":"2015","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib44","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: A randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety","volume":"43","author":"Falk","year":"2019","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib45","unstructured":"Fariba, K. A., & Saadabadi, A. (2023). Topiramate. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"key":"10.1016\/bs.irn.2024.02.002_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.927703","article-title":"Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review","volume":"13","author":"Fischler","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib47","doi-asserted-by":"crossref","first-page":"1085882","DOI":"10.3389\/fnbeh.2022.1085882","article-title":"Alternative use of suvorexant (Belsomra(\u00ae)) for the prevention of alcohol drinking and seeking in rats with a history of alcohol dependence","volume":"16","author":"Flores-Ramirez","year":"2022","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/bs.irn.2024.02.002_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jad.2015.06.024","article-title":"Depression in patients with alcohol use disorders: Systematic review and meta-analysis of outcomes for independent and substance-induced disorders","volume":"185","author":"Foulds","year":"2015","journal-title":"Journal of Affective Disorders"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib49","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1530-0277.2011.01628.x","article-title":"Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: Preliminary findings","volume":"36","author":"Fox","year":"2012","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"8666","key":"10.1016\/bs.irn.2024.02.002_bib50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","article-title":"Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome","volume":"2","author":"Gallimberti","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.irn.2024.02.002_bib51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"gamma-Hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib52","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12924","article-title":"The impact of varenicline on alcohol consumption in subjects with alcohol use disorders: Systematic review and meta-analyses","volume":"81","author":"Gandhi","year":"2020","journal-title":"The Journal of Clinical Psychiatry"},{"key":"10.1016\/bs.irn.2024.02.002_bib53","unstructured":"Gettu, N., & Saadabadi, A. (2023). Aripiprazole. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"key":"10.1016\/bs.irn.2024.02.002_bib54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1080\/08897077.2012.663326","article-title":"Is baclofen a revolutionary medication in alcohol addiction management? Review and recent updates","volume":"33","author":"Gorsane","year":"2012","journal-title":"Substance Abuse: Official Publication of the Association for Medical Education and Research in Substance Abuse"},{"key":"10.1016\/bs.irn.2024.02.002_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Epidemiology of DSM-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions III","author":"Grant","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/bs.irn.2024.02.002_bib56","unstructured":"Griddine, A., & Bush, J. S. (2023). Ondansetron. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jeffrey Bush declares no relevant financial relationships with ineligible companies. StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"10","key":"10.1016\/bs.irn.2024.02.002_bib57","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/02698811221104063","article-title":"Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Guiraud","year":"2022","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2024.02.002_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/acer.15014","article-title":"Utilizing precision medicine to treat alcohol use disorder: A commentary on the alpha1 receptor antagonist","author":"Haass-Koffler","year":"2023","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib59","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.03.016","article-title":"Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin","volume":"177","author":"Haass-Koffler","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib60","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/add.15329","article-title":"Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: A systematic review, meta-analysis and meta-regression","volume":"116","author":"Henssler","year":"2021","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib61","doi-asserted-by":"crossref","first-page":"e0183821","DOI":"10.1371\/journal.pone.0183821","article-title":"Harms associated with taking nalmefene for substance use and impulse control disorders: A systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Johansen","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: A randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Archives of General Psychiatry"},{"issue":"9370","key":"10.1016\/bs.irn.2024.02.002_bib63","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: A randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib64","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1530-0277.2000.tb02048.x","article-title":"Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: From hypotheses to preliminary clinical evidence","volume":"24","author":"Johnson","year":"2000","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib65","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","author":"Johnson","year":"2011","journal-title":"The American Journal of Psychiatry"},{"issue":"14","key":"10.1016\/bs.irn.2024.02.002_bib66","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence. A randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib67","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/appi.ajp.2013.12091163","article-title":"Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron","volume":"170","author":"Johnson","year":"2013","journal-title":"The American Journal of Psychiatry"},{"issue":"18","key":"10.1016\/bs.irn.2024.02.002_bib68","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.02.002_bib69","unstructured":"Kadian, R., & Kumar, A. (2023). Zonisamide. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Anil Kumar declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"4","key":"10.1016\/bs.irn.2024.02.002_bib70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/adb.12275","article-title":"Role of the \u03b11 blocker doxazosin in alcoholism: A proof-of-concept randomized controlled trial","volume":"21","author":"Kenna","year":"2016","journal-title":"Addiction Biology"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874473710902020135","article-title":"Review of topiramate: An antiepileptic for the treatment of alcohol dependence","volume":"2","author":"Kenna","year":"2009","journal-title":"Current Drug Abuse Reviews"},{"key":"10.1016\/bs.irn.2024.02.002_bib72","unstructured":"Kim, J., & Nguyen, H. (2023). Doxazosin. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Hoang Nguyen declares no relevant financial relationships with ineligible companies. StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"issue":"7","key":"10.1016\/bs.irn.2024.02.002_bib73","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","article-title":"Antipsychotics for primary alcohol dependence: A systematic review and meta-analysis of placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0000000000000246","article-title":"Zonisamide, topiramate, and levetiracetam: Efficacy and neuropsychological effects in alcohol use disorders","volume":"35","author":"Knapp","year":"2015","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib75","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.drugalcdep.2019.01.009","article-title":"Reduction in non-abstinent WHO drinking risk levels and depression\/anxiety disorders: 3-year follow-up results in the US general population","volume":"197","author":"Knox","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib76","doi-asserted-by":"crossref","first-page":"82","DOI":"10.70359\/bhc2008v033p082","article-title":"From disulfiram to antabuse: The invention of a drug","volume":"33","author":"Kragh","year":"2008","journal-title":"Bulletin for the History of Chemistry"},{"key":"10.1016\/bs.irn.2024.02.002_bib77","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2013.13081014","article-title":"Topiramate treatment for heavy drinkers: Moderation by a GRIK1 polymorphism","author":"Kranzler","year":"2014","journal-title":"The American Journal of Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib78","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"7","key":"10.1016\/bs.irn.2024.02.002_bib79","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early- versus late-onset alcoholics: A prospective, open-label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib80","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2018.11406","article-title":"Diagnosis and pharmacotherapy of alcohol use disorder: A review","volume":"320","author":"Kranzler","year":"2018","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.02.002_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2019.03.010","article-title":"Evaluation of N-acetylcysteine on ethanol self-administration in ethanol-dependent rats","volume":"150","author":"Lebourgeois","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib82","first-page":"CD006266","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","volume":"2","author":"Leone","year":"2010","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib83","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: A vision for the next decade","volume":"17","author":"Litten","year":"2012","journal-title":"Addiction Biology"},{"issue":"7","key":"10.1016\/bs.irn.2024.02.002_bib84","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/acer.13093","article-title":"Discovery, development, and adoption of medications to treat alcohol use disorder: Goals for the phases of medications development","volume":"40","author":"Litten","year":"2016","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib85","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction (Abingdon, England)"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/wps.20476","article-title":"Can reduced drinking be a viable goal for alcohol dependent patients?","volume":"16","author":"Mann","year":"2017","journal-title":"World Psychiatry: Official Journal of the World Psychiatric Association (WPA)"},{"key":"10.1016\/bs.irn.2024.02.002_bib88","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000481348","article-title":"Reduced drinking in alcohol dependence treatment, what is the evidence?","volume":"23","author":"Mann","year":"2017","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib89","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"12","key":"10.1016\/bs.irn.2024.02.002_bib90","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: Review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib91","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187152710790966641","article-title":"Acamprosate: A prototypic neuromodulator in the treatment of alcohol dependence","volume":"9","author":"Mason","year":"2010","journal-title":"CNS & Neurological Disorders Drug Targets"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib92","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib93","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.02.002_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109671","article-title":"Gabapentin to treat acute alcohol withdrawal in hospitalized patients: A systematic review and meta-analysis","volume":"241","author":"Mattle","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib95","article-title":"Alcohol use disorder and depressive disorders","volume":"40","author":"McHugh","year":"2019","journal-title":"Alcohol Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib96","first-page":"CD005064","article-title":"Anticonvulsants for alcohol withdrawal","volume":"3","author":"Minozzi","year":"2010","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1016\/bs.irn.2024.02.002_bib97","first-page":"Cd012557","article-title":"Baclofen for alcohol use disorder","volume":"11","author":"Minozzi","year":"2018","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"key":"10.1016\/bs.irn.2024.02.002_bib98","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pnpbp.2019.03.014","article-title":"Withdrawal effects following repeated ethanol exposure are prevented by N-acetylcysteine in zebrafish","volume":"93","author":"Mocelin","year":"2019","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"4","key":"10.1016\/bs.irn.2024.02.002_bib99","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archpsyc.65.4.466","article-title":"Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people","volume":"65","author":"Myrick","year":"2008","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/00952990.2012.730590","article-title":"Aripiprazole in an animal model of chronic alcohol consumption and dopamine D\u2082 receptor occupancy in rats","volume":"39","author":"Nirogi","year":"2013","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"7607","key":"10.1016\/bs.irn.2024.02.002_bib101","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib102","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/bs.irn.2024.02.002_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107631","article-title":"Efficacy and acceptability of varenicline for alcoholism: A systematic review and meta-analysis of randomized-controlled trials","volume":"205","author":"Oon-Arom","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.02.002_bib104","unstructured":"Padda, I. S., & Tripp, J. (2023). Phosphodiesterase Inhibitors. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Jayson Tripp declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."},{"key":"10.1016\/bs.irn.2024.02.002_bib105","article-title":"Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: A systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate","author":"Palpacuer","year":"2017","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.02.002_bib106","first-page":"Cd008544","article-title":"Anticonvulsants for alcohol dependence","volume":"2","author":"Pani","year":"2014","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/acer.12926","article-title":"Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: A clinical trial","volume":"40","author":"Petrakis","year":"2016","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"7","key":"10.1016\/bs.irn.2024.02.002_bib108","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2018.03.017","article-title":"Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis","volume":"28","author":"Pierce","year":"2018","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib109","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00406-017-0801-2","article-title":"Psychiatric comorbidity in alcohol use disorders: Results from the German S3 guidelines","volume":"268","author":"Preuss","year":"2018","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib111","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/acer.14989","article-title":"A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters","volume":"47","author":"Raskind","year":"2023","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib112","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/acer.13829","article-title":"Overcoming the \u201cvalley of death\u201d in medications development for alcohol use disorder","volume":"42","author":"Ray","year":"2018","journal-title":"Alcoholism, Clinical and Experimental Research"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib113","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/npp.2017.10","article-title":"Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: A randomized, placebo-controlled, human laboratory trial","volume":"42","author":"Ray","year":"2017","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib114","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1465-3362.2010.00185.x","article-title":"Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature","volume":"29","author":"Ray","year":"2010","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib115","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The american psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"The American Journal of Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib116","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: Efficacy, safety and place in therapy","volume":"6","author":"Rhyne","year":"2015","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"6","key":"10.1016\/bs.irn.2024.02.002_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098062","article-title":"Off-label baclofen prescribing practices among French alcohol specialists: Results of a national online survey","volume":"9","author":"Rolland","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/alcalc\/agz082","article-title":"France grants an approval to baclofen for alcohol dependence","volume":"55","author":"Rolland","year":"2020","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib119","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/add.14191","article-title":"Baclofen: Its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis","volume":"113","author":"Rose","year":"2018","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081216","article-title":"Distinct effects of nalmefene on dopamine uptake rates and kappa opioid receptor activity in the nucleus accumbens following chronic intermittent ethanol exposure","volume":"17","author":"Rose","year":"2016","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.irn.2024.02.002_bib121","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"9","author":"Rosner","year":"2010","journal-title":"Cochrane Database of Systematic Reviews (Online)"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0269881107078308","article-title":"Acamprosate supports abstinence, naltrexone prevents excessive drinking: Evidence from a meta-analysis with unreported outcomes","volume":"22","author":"Rosner","year":"2008","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib123","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2174\/0929867327666200831141337","article-title":"Perspectives on drug repurposing","volume":"28","author":"Schcolnik-Cabrera","year":"2021","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/bs.irn.2024.02.002_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108274","article-title":"Characteristics associated with denial of problem drinking among two generations of individuals with alcohol use disorders","volume":"217","author":"Schuckit","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"02","key":"10.1016\/bs.irn.2024.02.002_bib125","article-title":"A systematic review on drug re-profiling\/re-purposing","volume":"12","author":"Sharma","year":"2023","journal-title":"IARS\u2019 International Research Journal"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib126","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1254\/jphs.11201FP","article-title":"Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference","volume":"118","author":"Shibasaki","year":"2012","journal-title":"Journal of Pharmacological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib127","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.02.002_bib128","doi-asserted-by":"crossref","DOI":"10.1176\/appi.ajp.2018.17080913","article-title":"Double-blind randomized clinical trial of prazosin for alcohol use disorder","author":"Simpson","year":"2018","journal-title":"The American Journal of Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib129","doi-asserted-by":"crossref","first-page":"e13116","DOI":"10.1111\/adb.13116","article-title":"Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder","volume":"27","author":"Sinha","year":"2022","journal-title":"Addiction Biology"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1176\/appi.ajp.2020.20050609","article-title":"Moderation of Prazosin\u2019s efficacy by alcohol withdrawal symptoms","volume":"178","author":"Sinha","year":"2021","journal-title":"The American Journal of Psychiatry"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.drugalcdep.2010.06.011","article-title":"Effect of the threat of a disulfiram-ethanol reaction on cue reactivity in alcoholics","volume":"112","author":"Skinner","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/bs.irn.2024.02.002_bib133","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism\u2014An update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/bs.irn.2024.02.002_bib134","unstructured":"Soci\u00e9t\u00e9-Fran\u00e7aise-d\u2019Alcoologie. (2015). Good Practice recommendation\u2014Alcohol misuse: Screening, diagnosis and treatment. Retrieved from http:\/\/www.sfalcoologie.asso.fr\/download\/SFA-GPR-AlcoholMisuse.pdf?PHPSESSID=df10f34a19d19ef15f445823e499114a441145."},{"issue":"4","key":"10.1016\/bs.irn.2024.02.002_bib135","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/npp.2013.264","article-title":"Acamprosate produces its anti-relapse effects via calcium","volume":"39","author":"Spanagel","year":"2014","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.02.002_bib136","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","article-title":"The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial","volume":"185","author":"Squeglia","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.02.002_bib137","article-title":"Naltrexone: A history and future directions","volume":"2018","author":"Srivastava","year":"2018","journal-title":"Cerebrum: The Dana Forum on Brain Science"},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib138","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1517\/14656566.2011.589836","article-title":"Sodium oxybate for the treatment of fibromyalgia","volume":"12","author":"Staud","year":"2011","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1016\/bs.irn.2024.02.002_bib139","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2007.06.038","article-title":"Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse","volume":"75","author":"Tassin","year":"2008","journal-title":"Biochemical Pharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2024.02.002_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151242","article-title":"The combination of marketed antagonists of alpha1b-adrenergic and 5-HT2A receptors inhibits behavioral sensitization and preference to alcohol in mice: A promising approach for the treatment of alcohol dependence","volume":"11","author":"Trovero","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib141","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881113495320","article-title":"Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence","volume":"27","author":"Van Amsterdam","year":"2013","journal-title":"Journal of Psychopharmacology (Oxford, England)"},{"key":"10.1016\/bs.irn.2024.02.002_bib142","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13690-018-0254-8","article-title":"Utilization of gabapentin by people in treatment for substance use disorders in Belgium (2011\u20132014): A cross-sectional study","volume":"76","author":"Van Baelen","year":"2018","journal-title":"Arch Public Health"},{"key":"10.1016\/bs.irn.2024.02.002_bib143","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"Van Den Brink","year":"2018","journal-title":"Addiction Biology"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib144","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: Results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.02.002_bib145","article-title":"Effectiveness of drugs acting on adrenergic receptors in the treatment for tobacco or alcohol use disorders: Systematic review and meta-analysis","author":"Vanderkam","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"issue":"8","key":"10.1016\/bs.irn.2024.02.002_bib146","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI79828","article-title":"Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals","volume":"125","author":"Vendruscolo","year":"2015","journal-title":"The Journal of Clinical Investigation"},{"issue":"11","key":"10.1016\/bs.irn.2024.02.002_bib147","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Archives of General Psychiatry"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib148","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/0024-3205(86)90601-6","article-title":"Naltrexone blocks the post-shock increase of ethanol consumption","volume":"38","author":"Volpicelli","year":"1986","journal-title":"Life Sciences"},{"key":"10.1016\/bs.irn.2024.02.002_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/add.16126","article-title":"An intensive longitudinal examination of topiramate treatment for alcohol use disorder: A secondary analysis of data from a randomized controlled trial","author":"Votaw","year":"2023","journal-title":"Addiction (Abingdon, England)"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib150","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1523\/JNEUROSCI.22-09-03332.2002","article-title":"Behavioral neurobiology of alcohol addiction: Recent advances and challenges","volume":"22","author":"Weiss","year":"2002","journal-title":"The Journal of Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2024.02.002_bib151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ADM.0000000000000413","article-title":"A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder","volume":"12","author":"Wilcox","year":"2018","journal-title":"Journal of Addiction Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib152","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/add.15011","article-title":"World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom","volume":"115","author":"Witkiewitz","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/bs.irn.2024.02.002_bib153","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s11606-020-06331-x","article-title":"Stability of drinking reductions and long-term functioning among patients with alcohol use disorder","volume":"36","author":"Witkiewitz","year":"2021","journal-title":"Journal of General Internal Medicine: Official Journal of the Society for Research and Education in Primary Care Internal Medicine"},{"issue":"9","key":"10.1016\/bs.irn.2024.02.002_bib154","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Science Advances"},{"issue":"10","key":"10.1016\/bs.irn.2024.02.002_bib155","first-page":"13870","article-title":"Who achieves low risk drinking during alcohol treatment? An analysis of patients in three alcohol clinical trials","volume":"16","author":"Witkiewitz","year":"2017","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.02.002_bib156","unstructured":"Yasaei, R., Katta, S., & Saadabadi, A. (2023). Gabapentin. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Shravan Katta declares no relevant financial relationships with ineligible companies. Disclosure: Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies. StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC."}],"container-title":["International Review of Neurobiology","The neurobiology of alcohol use disorder: Neuronal mechanisms, current treatments and novel developments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:14:40Z","timestamp":1753362880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443141645"],"references-count":156,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.02.002","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}